Cost of Exempting Sole Orphan Drugs From Medicare Negotiation.

Vogel M, Zhao O, Feldman WB, Chandra A, Kesselheim AS, Rome BN

DOI: 10.1001/jamainternmed.2023.6293
Published: 2024 Jan 1
Container: JAMA internal medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1001/jamainternmed.2023.6293,
  title = {Cost of Exempting Sole Orphan Drugs From Medicare Negotiation.},
  author = {Vogel M and Zhao O and Feldman WB and Chandra A and Kesselheim AS and Rome BN},
  year = {2024},
  journal = {JAMA internal medicine},
  doi = {10.1001/jamainternmed.2023.6293},
  url = {https://doi.org/10.1001/jamainternmed.2023.6293}
}

RIS

TY  - JOUR
TI  - Cost of Exempting Sole Orphan Drugs From Medicare Negotiation.
AU  - Vogel M
AU  - Zhao O
AU  - Feldman WB
AU  - Chandra A
AU  - Kesselheim AS
AU  - Rome BN
PY  - 2024
JO  - JAMA internal medicine
DO  - 10.1001/jamainternmed.2023.6293
UR  - https://doi.org/10.1001/jamainternmed.2023.6293
ER  -

APA

M, V., O, Z., WB, F., A, C., AS, K., & BN, R. (2024). Cost of Exempting Sole Orphan Drugs From Medicare Negotiation.. JAMA internal medicine. https://doi.org/10.1001/jamainternmed.2023.6293

Source records

pubmed · retrieved 2026-09-26T14:09:09.109Z